| IceCure Medical: IceCure Reports 70% Growth in Active U.S. Commercial Install Base for Breast Cancer Cryoablation Following FDA Clearance | Increase driven by FDA clearance, clinical guideline support, and increased physician demand. Significant rise in number of leads for ProSense® systems generated... ► Artikel lesen |
| IceCure Medical Announces 1-for-30 Reverse Share Split to Support Nasdaq Compliance | Proactive Step to Regain Nasdaq Compliance as Part of the Company's Broader Capital Markets Strategy
CAESAREA, ISRAEL, June 2, 2026 /PRNewswire/ -- IceCure Medical... ► Artikel lesen |
| IceCure Medical: IceCure's ProSense Reports Nearly 90% Recurrence-Free Rate for Cryoablation of Kidney Cancer: Data Presented at ECIO 2026 and First-Ever Breast Cryoablation Master Class Overbooked | At the annual European Conference on Interventional Oncology, ICESECRET data presented demonstrated 89.4% recurrence-free rate in patients with tumors =3 cm and... ► Artikel lesen |
| PROCEPT BioRobotics Reports First Quarter 2026 Financial Results | SAN JOSE, Calif., April 29, 2026 (GLOBE NEWSWIRE) -- PROCEPT BioRobotics® Corporation (Nasdaq: PRCT) (the "Company"), a surgical robotics company focused on advancing patient care by developing transformative... ► Artikel lesen |
| PROCEPT BioRobotics: EAU Guidelines Upgrade Aquablation Therapy to Strong Surgical Recommendation for BPH | Updated European Association of Urology guidelines reflect growing clinical evidence supporting Aquablation therapy in the surgical treatment of benign prostatic hyperplasiaSAN JOSE, Calif., March 23... ► Artikel lesen |
| PROCEPT BioRobotics Announces International Launch of the HYDROS Robotic System, Expanding Global Access to AI-Enabled Aquablation Therapy | UK marks first international launch of the HYDROS Robotic System, with additional international expansion planned in 2026SAN JOSE, Calif., March 12, 2026 (GLOBE NEWSWIRE) -- PROCEPT BioRobotics (Nasdaq:... ► Artikel lesen |